Alocyte low dose
Phase 1Small molecule
Alocyte low dose is one of 43 small molecule programs targeting Back pain. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
87 competitors in Back Pain
#DrugCompanyPhaseTrials
1Toradol
RocheApproved
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Buprenorphine/naloxone
AstellasApproved
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Aspercreme Warming
AAveritas Pharma, Inc.
Phase 3
Suboxone
IIndivior Inc.
Phase 3
Botox
AbbViePhase 3
Buprenorphine IV
PPurdue Pharma LP
Phase 3
Standard Medical Care
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Alocyte low dose. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- AAlimorad Farshchian